These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34101630)

  • 1. Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia.
    Jin F; Amin J; Guy R; Vaccher S; Selvey C; Zablotska I; Holden J; Price K; Yeung B; Ogilvie E; Quichua GC; Clackett S; McNulty A; Smith D; Templeton DJ; Bavinton B; Grulich AE;
    AIDS; 2021 Oct; 35(12):1987-1996. PubMed ID: 34101630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.
    Grulich AE; Jin F; Bavinton BR; Yeung B; Hammoud MA; Amin J; Cabrera G; Clackett S; Ogilvie E; Vaccher S; Vickers T; McNulty A; Smith DJ; Dharan NJ; Selvey C; Power C; Price K; Zablotska I; Baker DA; Bloch M; Brown K; Carmody CJ; Carr A; Chanisheff D; Doong N; Finlayson R; Lewis DA; Lusk J; Martin S; Ooi C; Read P; Ryder N; Smith D; Tuck Meng Soo C; Templeton DJ; Vlahakis E; Guy R;
    Lancet HIV; 2021 Aug; 8(8):e486-e494. PubMed ID: 34217426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus-Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings From the Expanded PrEP Implementation in Communities-New South Wales Prospective Implementation Study.
    Amin J; Vaccher S; Templeton DJ; Bavinton B; Jin F; Zablotska I; Matthews G; Ogilvie E; Yeung B; Ooi C; Dharan N; Baker DA; Read P; Guy R; Grulich AE
    Clin Infect Dis; 2022 Oct; 75(9):1497-1502. PubMed ID: 35352102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Human Immunodeficiency Virus (HIV) Seroconversions in a Large Prospective Implementation Cohort Study of Oral HIV Preexposure Prophylaxis in Men Who Have Sex with Men (EPIC-NSW).
    Dharan NJ; Jin F; Vaccher S; Bavinton B; Yeung B; Guy R; Carr A; Zablotska I; Amin J; Read P; Templeton DJ; Ooi C; Martin SJ; Ryder N; Smith DE; McNulty A; Brown K; Price K; Holden J; Grulich AE;
    Clin Infect Dis; 2023 Feb; 76(3):e622-e628. PubMed ID: 35982613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
    McManus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; McNulty A; Smith D; Guy R
    JAMA Netw Open; 2020 Dec; 3(12):e2030806. PubMed ID: 33355675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: results from the MI-EPIC clinical trial.
    Chan C; Fraser D; Vaccher S; Yeung B; Jin F; Amin J; Dharan NJ; Carr A; Ooi C; Vaughan M; Holden J; Power C; Grulich AE; Bavinton BR;
    Sex Health; 2022 Jan; 18(6):453-459. PubMed ID: 34895427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of government subsidized HIV pre-exposure prophylaxis in Australia: a whole-of-population analysis of dispensing records.
    Medland NA; Fraser D; Bavinton BR; Jin F; Grulich AE; Paynter H; Guy R; McManus H
    J Int AIDS Soc; 2023 Jan; 26(1):e26056. PubMed ID: 36707247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
    Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
    J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
    Traeger MW; Guy R; Asselin J; Patel P; Carter A; Wright EJ; Grulich A; McManus H; Fairley CK; Chow EPF; McNulty A; Finlayson R; Bell C; Owen L; Marshall L; Russell D; O'Donnell D; Donovan B; Hellard ME; Stoové MA;
    Lancet Infect Dis; 2022 Aug; 22(8):1231-1241. PubMed ID: 35643090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Levels of Prevention-Effective Adherence to HIV PrEP: An Analysis of Substudy Data From the EPIC-NSW Trial.
    Bavinton BR; Vaccher S; Jin F; Prestage GP; Holt M; Zablotska-Manos IB; Guy R; Amin J; Templeton DJ; Yeung B; Hammoud MA; Lewis D; Baker D; Dharan N; McNulty AM; Grulich AE;
    J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1040-1047. PubMed ID: 33852503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study.
    Konda KA; Torres TS; Mariño G; Ramos A; Moreira RI; Leite IC; Cunha M; Jalil EM; Hoagland B; Guanira JV; Benedetti M; Pimenta C; Vermandere H; Bautista-Arredondo S; Vega-Ramirez H; Veloso VG; Caceres CF; Grinsztejn B;
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25974. PubMed ID: 36225148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
    Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
    J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
    Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
    PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study.
    Veloso VG; Cáceres CF; Hoagland B; Moreira RI; Vega-Ramírez H; Konda KA; Leite IC; Bautista-Arredondo S; Vinícius de Lacerda M; Valdez Madruga J; Farias A; Lima JN; Zonta R; Lauria L; Tamayo CVO; Flores HJS; Santa Cruz YMC; Aguayo RMM; Cunha M; Moreira J; Makkeda AR; Díaz S; Guanira JV; Vermandere H; Benedetti M; Ingold HL; Pimenta MC; Torres TS; Grinsztejn B;
    Lancet HIV; 2023 Feb; 10(2):e84-e96. PubMed ID: 36565708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.